Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
87°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
89.64
-0.28 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and...
Via
Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
The price could be right for these three biopharma stocks.
Via
The Motley Fool
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Via
The Motley Fool
Earnings Outlook For Axsome Therapeutics
February 19, 2024
Via
Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
February 06, 2024
Via
Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
January 16, 2024
Via
Benzinga
Analyst Expectations for Axsome Therapeutics's Future
November 07, 2023
Via
Benzinga
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
AXSM earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.
Via
Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
February 20, 2024
The company is testing a treatment for patients with agitation due to Alzheimer's disease.
Via
Investor's Business Daily
2 Stocks That Could Double Your Money in 5 Years
February 08, 2024
These market-beating stocks could be just getting started.
Via
The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
January 26, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Earnings Scheduled For February 20, 2024
February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Via
Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
January 25, 2024
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.
Via
Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
January 03, 2024
Is it too late to invest in these fast-growing stocks?
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
January 02, 2024
The types of innovative drugs these companies develop are always in high demand.
Via
The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
January 01, 2024
Investors could enjoy an especially happy new year with these great stocks.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Right Now
December 10, 2023
These stocks could be just the ticket for investors seeking strong growth.
Via
The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
November 11, 2023
Investors shouldn't have to deliberate for too long about these great stocks.
Via
The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
November 09, 2023
Can these promising growth stocks continue rising in value?
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
November 06, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m
Via
Benzinga
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
November 06, 2023
AXSM earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Riding the Wave: 3 Stocks That Can 10X by 2025
October 30, 2023
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.